

HPLC Method for Analysis of Evogliptin in Pharmaceutical Dosage Form on Primesep B Column



Evogliptin is a drug that belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors. It is used primarily for the treatment of type 2 diabetes mellitus. DPP-4 inhibitors work by blocking the action of the enzyme DPP-4, which in turn increases the levels of incretin hormones such as GLP-1 (glucagon-like peptide-1). This increase helps to stimulate insulin release and suppress glucagon secretion, thereby helping to regulate blood sugar levels in patients with diabetes.

Evogliptin can be retained, and analyzed using a Primesep B mixed-mode stationary phase column. The analysis utilizes an isocratic method with a simple mobile phase consisting of water, acetonitrile (MeCN), and sulfuric acid as a buffer. Detection is achieved using UV at 200 nm

Method Parameters

Column	Primesep B, 4.6 x 150 mm, 5 µm, 100 Å, dual ended
Mobile Phase	MeCN/H ₂ O – 15/85%
Buffer	H ₂ SO ₄ -0.2%
Flow Rate	1.0 mL/min
Detection	UV 300 nm

Quelle: <https://sielc.com/hplc-method-for-analysis-evogliptin>